Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Brentuximab→

Brentuximab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
775303-41-8
FDA UNII
C67ORA155P
PubChem Substance Record
SID 505565949
Other names
SGN-30; cAC10; CAC-10; CAC10

Identification sources: NCATS Inxight substance record and PubChem Brentuximab record (SID 505565949). The records identify Brentuximab as an anti-CD30 monoclonal antibody. PubChem does not assign a discrete CID; its record does not list a molecular formula or molecular weight.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Brentuximab Environmental Risk Assessment (ERA) (the Brentuximab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.